| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6198970 | Ophthalmology | 2016 | 11 Pages |
Abstract
Vision gains during the first 2 years were not maintained at 5 years. However, 50% of eyes had VA of 20/40 or better, confirming anti-vascular endothelial growth factor therapy as a major long-term therapeutic advance for neovascular AMD.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Maureen G. PhD, Daniel F. MD, Gui-shuang PhD, Glenn J. MD, Ebenezer MBBS, PhD,